IMDX
Insight Molecular Diagnostics Inc.
NASDAQ · USHealthcareBiotechnology
$4.84+2.11%
Price as of Jul 20, 2026
IMDX financials
Insight Molecular Diagnostics Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $4.1M | $1.9M | $1.5M | $958.0K |
| Cost of revenue | $3.9M | $1.1M | $1.1M | $976.0K |
| Gross profit | $190.0K | $740.0K | $413.0K | -$18.0K |
| Operating expenses | $30.8M | $61.8M | $25.5M | $18.0M |
| Operating income | -$30.6M | -$61.0M | -$25.1M | -$18.0M |
| Net income | -$50.2M | -$60.7M | -$27.8M | -$72.9M |
| EBITDA | -$47.9M | -$59.0M | -$23.1M | -$13.3M |
| Basic EPS | $-1.65 | $-4.66 | $-3.75 | $-20.00 |
| Diluted EPS | $-1.65 | $-4.66 | $-3.75 | $-20.00 |
| Balance sheet | ||||
| Cash & equivalents | $11.6M | $8.6M | $9.4M | $20.0M |
| Total assets | $25.8M | $35.1M | $74.9M | $100.1M |
| Total liabilities | $57.2M | $47.4M | $54.4M | $60.5M |
| Stockholders’ equity | -$31.5M | -$12.3M | $20.5M | $39.6M |
| Total debt | $3.5M | $3.7M | $2.9M | $3.5M |
| Net debt | -$8.1M | -$5.0M | -$6.6M | -$16.4M |
| Cash flow | ||||
| Operating cash flow | -$22.2M | -$20.7M | -$23.3M | -$45.6M |
| Capital expenditure | -$3.2M | -$516.0K | -$281.0K | -$4.3M |
| Free cash flow | -$25.4M | -$21.2M | -$23.6M | -$49.9M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |